Member Info for EXMEX

Well one things for sure PI101 , you've totally failed with that year end share price target you posted.

P101, you seek to compare the company with five years ago . You make no mention that there was only 37 million shares in issue on admission to AIM with a MC of £22 million. Even at today's prices the company is valued at double that .

Well one things for sure there shouldn't be many overlapping jobs if any m+a is completed in the near future. The workforce has been reduced right across the company, down by approximately another thirty since the start of autumn.

Hi Wilson, you could always check out this link to the Dublin street music scene while we wait for some news.
https://youtu.be/QQcVwsjaUSE

It would appear that Hampshire is seeing increasing numbers of Strep A, especially on the Isle of White. Do those doctors and NHS staff on the Isle of White know that there is a company across the Solent with the very product they need for quick diagnosis, or are they completely in the dark?
https://www.hampshirelive.news/news/hampshire-news/hampshires-worst-areas-strep-scarlet-7919611

Hi Kaeren, as far as I know this is the link to the UNICEF meeting of supplier's the other week .If you click on the draft agenda there are full details of the programme. On the last page it states that one to one meetings with the relevant agency would be taking place on day four . Did Novacyt attend one of these?
https://extranet.who.int/pqweb/events/joint-unicef-unfpa-who-meeting-manufacturers-and-suppliers-0

21ATS, as far as I know a professional use test will have been validated as part of it's trial in a clinical setting to arrive at the performance figures ( sensitivity and specificity). Whereas a test intended for use by the general public will have been proven in that type of non clinical setting and could have different performance figures due to how well the test is carried out. If anybody knows of anything else please add .

Kaeren, thanks for the reply.

Could Clonit be conducting validation of their assays on the q devices, in parallel with what Novacyt are currently doing to provide a separate performance report. Just a thought.

Sorry B2HS2L, I didn't see your link.

Another summary of Edwin Snape's career history is available on this link.
https://nmtcapital.com/team.html#Principals

No competition Huey, I posted that review as balance to your narrative as you chose to ignore it .Seems you don't believe everything on that site after all.

Hi KT, several NHS hospitals were running pilot programmes using Novacyts NTP system (this used exsig direct) in July 2020 nine weeks before the main contract was awarded. From the rns 27/07/20

Great working culture. Excellent communication between different departments. Forward thinking managers. Market leading research and development. Excellent company to work for . Competitive salary.
Now where would you find a review for Novacyt like that ,posted on December 3rd 2022.

Huey, you state that Novacyt need an e-commerce platform when they have already said one was launched in Q2 this year. Who's right ,you or the company?
The RUO portfolio was relaunched in July this year with the assays proven to do what they are supposed to . Out of the RUO portfolio 250 assays have been prioritised and these are available on a seven day turn round . The remainder are on a longer lead time.
You also made the comment that Novacyt should be launching some these as IVDR clinical tests.How do you propose to circumvent the backlog in the EU approval process? That's why access to the Clonit assays is a positive while Novacyts tests work their way through regulatory approval .
Regarding that site you are using for job reviews, doesn't anonymity reign supreme.

P101 there's plenty to discuss about those assays and the new testing markets these will enable Novacyt to enter as they transition away from being a mainly RUO test developer to a clinical test developer. However I'm not surprised you don't want to discuss it as that would totally undermine your narrative that they haven't got any products to sell other than covid tests.

P101, why do you never discuss the Clonit partnership that Novacyt announced at the end of September .Forty plus CE IVDR clinical assays assays that Novacyt have full access to .
A question you you should be asking is why did Clonit agree to such a deal if their products are going to be gradually superceded by new ones from Novacyt .

The best source of info regarding current respiratory infections in the UK is the UKHSA weekly influenza report which is published each Friday. The week 46 report show's two strains of influenza A in circulation, but at the moment they don't know which one will become the dominant strain.

Well worth reading question two of the transcript from a meeting of the public accounts committee dated 18/05/22. In this they discuss the Oxford nanopore contract dispute with the DHSC. Tests from this contract awarded two months before Novacyts were planned for use in similar settings but were never rolled out at scale like those from Novacyt.The statement at the end said this didn't happen because newer tests were coming on the market .The final sentence summed up the direction testing had now taken- We are now very used to using lateral flow tests , which have taken precedence.
https://committees.parliament.uk/event/13552/formal-meeting-oral-evidence-session/
Just click on the transcript

Companies House records were updated with the departure of DA early last week, but as you say their website has never been updated.